The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family
that is abnormally activated in many epithelial tumors. Several mechanisms lead to the …

Purpose Early clinical studies with gefitinib showed promising efficacy and mild toxicity in
patients with advanced non–small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Non–small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an
attractive potential target for novel therapeutic inhibition in human cancers. We provide …

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the
most important targets for drug development in oncology. Monoclonal antibodies targeting …

Background Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during …

Purpose To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line
treatment of advanced non–small-cell lung cancer (NSCLC). Patients and Methods This …

Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB
receptor family that is abnormally activated in many epithelial tumors. The aberrant …

Multiple cellular pathways influence the growth and metastatic potential of tumors. This
creates heterogeneity, redundancy, and the potential for tumors to bypass signaling pathway …